Loading stock…

Dermapharm Holding SE (DMP) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Dermapharm Holding SE

DMPMarket cap $2.13BPrice $42.9

Country🇩🇪Germany

SectorHealthcare

IndustryPharmaceuticals

Develops and manufactures branded generic drugs, dermatology products, and vitamins across Germany and Europe. Skips the risky patent-drug lottery entirely, instead building a cash-generating portfolio of household-name pharma brands most patients trust without ever knowing they're "generics."

In Bastion Portfolios?

52W Return+12%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+8%6

Revenue Forecast

Rev CAGR (1y)-1%2

Rev CAGR (3y)+4%3

Rev CAGR (5y)+4%4

Earnings Forecast

EPS Growth Y+1+6%6

EPS Growth Y+2+16%8

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin21%8

Net Income Margin12%6

Free Cash Flow Margin18%8

Debt

Net Debt/EBITDA3.13

Efficiency

ROE26%9

ROA7%7

Earnings Stability55

GEAR+STRONG75

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)137

P/E Ratio (Forward 3y)117

P/BV3.54

EV Multiples

EV/EBITDA Fwd87

EV/EBIT Fwd118

Yield

Free Cash Flow Yield11.4%9

Dividend Yield2.3%6

Momentum

Short term

1 month return-2%7

3 month return-20%2

YTD return-2%4

Mid term

Price vs 52wHigh75%4

1 year return+17%7

Long term

3 year return+4%3

5 year return-48%1

Risk Shield

Price Risk

Beta0.39

Volatility30%7

Free Cash Flow

Free Cash Flow Margin18%8

Free Cash Flow Yield11.4%9

Quality

ROCE14%7

Earnings Stability55

Net Debt/EBITDA3.13

02Growth

Is it actually growing, and how fast?

DMPDermapharm Holding

Revenue FY25$1.4B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+6%6

EPS growth, FY27E+16%8

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 9%/yr vs revenue 4%/yr), so margins should widen.

WATCH

Revenue grew 8%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

DMPDermapharm Holding

Total return Current91.5%

Price return Current65.0%

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return-20%2

YTD return-2%4

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return+17%7

3-year return+4%3

5-year return-48%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-2%).

WATCH

It's up 17% over the past year, but 25% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level so far this year (-2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+4.3% over three years and -48% over five), behind 80% of the market.

The stock is underperforming over three months (-20%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Dermapharm Holding SE. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

DMPDermapharm Holding

Revenue FY25$1.4B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+6%6

EPS growth, FY27E+16%8

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 9%/yr vs revenue 4%/yr), so margins should widen.

WATCH

Revenue grew 8%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

DMPDermapharm Holding

Total return Current91.5%

Price return Current65.0%

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return-20%2

YTD return-2%4

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return+17%7

3-year return+4%3

5-year return-48%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-2%).

WATCH

It's up 17% over the past year, but 25% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level so far this year (-2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+4.3% over three years and -48% over five), behind 80% of the market.

The stock is underperforming over three months (-20%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Dermapharm Holding SE. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community